Osmulski, P. A., and Gaczynska, M. (2000). Atomic force microscopy reveals two conforma- tions of the 20S proteasome from fission yeast. J. Biol. Chem. 275, 13171–13174. Osmulski, P. A., and Gaczynska, M. (2002). Nanoenzymology of the 20S proteasome: Proteasomal actions are controlled by the allosteric transition. Biochemistry 41, 7047–7053. Santos, N. C., and Castanho, M. A. (2004). An overview of the biophysical applications of atomic force microscopy. Biophys. Chem. 107, 133–149. Thess, A., Hutschenreiter, S., Hofmann, M., Tampe, R., Baumeister, W., and Guckenberger, R. (2002). Specific orientation and two‐dimensional crystallization of the proteasome at metal‐chelating lipid interfaces. J. Biol. Chem. 277, 36321–36328. Unno, M., Mizushima, T., Morimoto, Y., Tomisugi, Y., Tanaka, K., Yasuoka, N., and Tsukihara, T. (2002). Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 A resolution. J. Biochem. 131, 171–173. Viani, M. B., Pietrasanta, L. I., Thompson, J. B., Chand, A., Gebeshuber, I. C., Kindt, J. H., Richter, M., Hansma, H. G., and Hansma, P. K. (2000). Probing protein‐protein interactions in real time. Nature Struct. Biol. 7, 644–647. Vie, V., Van Mau, N., Pomarede, P., Dance, C., Schwartz, J. L., Laprade, R., Frutos, R., Rang, C., Masson, L., Heitz, F., and Le Grimellec, C. (2001). Lipid‐induced pore formation of the Bacillus thuringiensis Cry1Aa insecticidal toxin. J. Membr. Biol. 180, 195–203. Whitby, F. G., Masters, E. I., Kramer, L., Knowlton, J. R., Yao, Y., Wang, C. C., and Hill, C. P. (2000). Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115–120. Yang, Y., Wang, H., and Erie, D. A. (2003). Quantitative characterization of biomolecular assemblies and interactions using atomic force microscopy. Methods 29, 175–187. Zwickl, P., Seemuller, E., Kapelari, B., and Baumeister, W. (2001). The proteasome: A supramolecular assembly designed for controlled proteolysis. Adv. Prot. Chem. 59, 187–222. [35] Characterization of Noncompetitive Regulators of Proteasome Activity By MARIA GACZYNSKA and PAWEL A. OSMULSKI Abstract The success of bortezomib, a competitive proteasome inhibitor and a drug approved to treat multiple myeloma, spurred interest in compounds targeting catalytic sites of the enzyme. The aim of this chapter, however, is to focus attention on the small molecule, natural or synthetic compounds binding far away from the catalytic centers, yet modifying the performance of the proteasome. Defining allostery broadly as any kind of ligand‐ induced, long‐distance transfer of conformational signals within a molecule, most such compounds are allosteric effectors capable of regulating the proteasome in vitro and in vivo in a manner more diverse and precise than competitive inhibitors. Proline‐ and arginine‐rich peptides (PR peptides) are examples of such compounds and are currently being considered as [35] noncompetitive regulators of the proteasome 425 METHODS IN ENZYMOLOGY, VOL. 398 0076-6879/05 $35.00 Copyright 2005, Elsevier Inc. All rights reserved. DOI: 10.1016/S0076-6879(05)98035-X